Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

July 2022 | 51 pages | ID: AA339AA012E7EN
Global Markets Direct

Abstracts

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Adrenocorticotropic Hormone Receptor - Drugs In Development, 2022'; Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - The adrenocorticotropic hormone receptor also known as the melanocortin receptor 2 is a type of melanocortin receptor (type 2) which is specific for ACTH. ACTH receptor is found in the zona fasciculata of adrenal cortex. Binding of the receptor by ACTH stimulates the production of cortisol.

The report 'Adrenocorticotropic Hormone Receptor - Drugs In Development, 2022' outlays comprehensive information on the Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Discovery stages are 1, 2 and 2 respectively. Report covers products from therapy areas Hormonal Disorders, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders and Undisclosed which include indications Congenital Adrenal Hyperplasia (Adrenogenital Syndrome), Endocrine Gland Disorders, IgA Nephropathy (Berger's Disease), Infantile Spasm (West Syndrome), Pituitary ACTH Hypersecretion (Cushing Disease) and Unspecified.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
• The report reviews Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and @Scope

Contents

Introduction
Global Markets Direct Report Coverage
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Overview
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Companies Involved in Therapeutics Development
Crinetics Pharmaceuticals Inc
Ferring Pharmaceuticals Inc
Mallinckrodt Plc
OMass Therapeutics Limited
Upsher-Smith Laboratories LLC
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Drug Profiles
AMZ-002 - Drug Profile
Product Description
Mechanism Of Action
History of Events
corticotropin - Drug Profile
Product Description
Mechanism Of Action
History of Events
corticotropin - Drug Profile
Product Description
Mechanism Of Action
cosyntropin SR - Drug Profile
Product Description
Mechanism Of Action
History of Events
CRN-04894 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MC2 - Drug Profile
Product Description
Mechanism Of Action
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Dormant Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Discontinued Products
Adrenocorticotropic Hormone Receptor (Adrenocorticotropin Receptor or Melanocortin Receptor 2 or ACTHR or MC2R) - Product Development Milestones
Featured News & Press Releases
May 25, 2022: Crinetics Pharmaceuticals reports positive top-line results including strong adrenal suppression from CRN04894 phase 1 study multiple-ascending dose cohorts
May 17, 2022: New retrospective data on African Americans with advanced symptomatic sarcoidosis treated with Acthar Gel (repository corticotropin injection) presented at the American Thoracic Society Annual International Conference
Dec 02, 2021: Amzell and Amring Pharmaceuticals attending 2021 American Epilepsy Society Meeting in Chicago
Nov 19, 2021: Amzell in collaboration With Amring Pharmaceuticals announce their lead product has entered Phase III clinical trial in the U.S. for treatment of infantile epileptic disease
Nov 17, 2021: Options for those who suffer from rheumatoid arthritis as new research reflects the benefit of repository corticotropin injection (RCI) to Real-World Clinical Outcomes
Aug 10, 2021: Crinetics Pharmaceuticals’ oral ACTH antagonist, CRN04894, demonstrates pharmacologic proof-of-concept with dose-dependent cortisol suppression in single ascending dose portion of phase 1 study
Jul 01, 2021: Mallinckrodt announces inclusion of Acthar Gel (Repository Corticotropin Injection) in New European Respiratory Society (ERS) treatment guidelines for patients with pulmonary sarcoidosis
May 03, 2021: Mallinckrodt presents data evaluating Acthar Gel (Repository Corticotropin Injection) for the treatment of severe keratitis at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting
Feb 04, 2021: Crinetics Pharmaceuticals lead ACTH antagonist for congenital adrenal hyperplasia and Cushing’s disease (CRN04894) advances into phase 1 study
Nov 16, 2020: AMZELL to initiate FDA-approved Phase 3 trial of innovative injectable treatment for infantile epileptic disease
Oct 20, 2020: City of Rockford $10 billion lawsuit against pharmaceutical giant Mallinckrodt threatened by bankruptcy
Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
Jun 15, 2020: Mallinckrodt to proceed with appeal despite appellate court decision denying temporary injunction in ongoing Acthar Gel medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
Jun 01, 2020: Mallinckrodt will appeal District Court ruling in case involving ongoing Acthar medicaid drug rebate dispute with the Centers for Medicare and Medicaid Services (CMS)
Apr 15, 2020: Mallinckrodt announces publication of data on Acthar Gel (Repository Corticotropin Injection) from its randomized, double-blind, placebo-controlled phase 4 study in rheumatoid arthritis (RA) in Rheumatology and Therapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Crinetics Pharmaceuticals Inc, 2022
Pipeline by Ferring Pharmaceuticals Inc, 2022
Pipeline by Mallinckrodt Plc, 2022
Pipeline by OMass Therapeutics Limited, 2022
Pipeline by Upsher-Smith Laboratories LLC, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022